The Liver Meeting 2020-Liver Fibrosis SIG NASH Fibrosis: From Matrix to Medicine

Video Transcription

Video Summary

The video features presentations by experts on liver fibrosis in NASH, each focusing on different aspects. Henderson discussed the molecular pathways leading to fibrosis in NASH, emphasizing the dysregulation of repair processes. Tack explored immune-mediated regulation of fibrosis, particularly the role of liver macrophages. Cai highlighted how the hepatocyte cholesterol test pathway promotes a pro-fibrogenic state in NASH. Meanwhile, Tabas discussed cholesterol metabolism in driving fibrosis progression and the importance of identifying regulators like EHBP1. Seki focused on hyaluronan as a biomarker for liver fibrosis, detailing its production and degradation processes and the efficacy of inhibiting its synthesis in reducing fibrosis. Both researchers stressed the need for non-invasive biomarkers for fibrosis staging and monitoring treatment, suggesting collagen fragments, hyaluronan, and specific microRNAs as potential options. Seki recommended exploring treatments targeting hyaluronan synthesis to combat NASH fibrosis.

Keywords

liver fibrosis

NASH

molecular pathways

repair processes

immune-mediated regulation

liver macrophages

hepatocyte cholesterol test pathway

pro-fibrogenic state

cholesterol metabolism

fibrosis progression

EHBP1

hyaluronan

biomarkers